Health
Regeneron halts trial of antibody treatment in seriously ill Covid patients – Financial Times
Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases
Regeneron has stopped enrolling seriously ill Covid-19 patients in a clinical trial of the antibody treatment that US President Donald Trump has hailed as a “cure” for the disease.
Shares in Regeneron fell as much as 3 per cent after an independent data monitoring committee warned that the risks might outweigh the benefits for hospitalised patients on high levels of oxygen.
The move comes after Eli Lilly, which is also developing a Covid-19 antibody treatment, stopped its trial in hospitalised…
-
Noosa News21 hours agoThis 42-Kilometre Walking Trail on the NSW North Coast Weaves Through Ancient Rainforest, Volcanic Mountains and Spectacular Waterfalls
-
Noosa News23 hours agoJane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
Noosa News22 hours agoGabby Petito died after experiencing domestic violence. Young Aussies are identifying with her story
-
General23 hours agoNo ‘band-aid solution’: sweating coal risky business